(Q51736472)

11 April 2018

title

Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. (English)

1 reference

11 April 2018

main subject

phase I clinical trial

0 references

1 reference

15

Carl H June

1 reference

11 April 2018

Bruce L. Levine

12

object named as

Bruce L Levine

1 reference

11 April 2018

Simon F Lacey

3

object named as

Simon F Lacey

1 reference

11 April 2018

author name string

Gregory L Beatty

1

1 reference

11 April 2018

Mark H O'Hara

2

1 reference

11 April 2018

Drew A Torigian

4

1 reference

11 April 2018

Farzana Nazimuddin

5

1 reference

11 April 2018

Fang Chen

6

1 reference

11 April 2018

Irina M Kulikovskaya

7

1 reference

11 April 2018

Michael C Soulen

8

1 reference

11 April 2018

Maureen McGarvey

9

1 reference

11 April 2018

Anne Marie Nelson

10

1 reference

11 April 2018

Whitney L Gladney

11

1 reference

11 April 2018

J Joseph Melenhorst

13

1 reference

11 April 2018

Gabriela Plesa

14

1 reference

11 April 2018

language of work or name

English

0 references

publication date

19 March 2018

1 reference

11 April 2018

published in

Gastroenterology

1 reference

11 April 2018

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Discovery of mesothelin and exploiting it as a target for immunotherapy

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Signatures of mutational processes in human cancer

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6035088

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

2 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29567081

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1053/J.GASTRO.2018.03.029

1 reference

11 April 2018

PMC publication ID

6035088

0 references

1 reference

11 April 2018